Targeted Oncology8 小时
Olomorasib Combo Elicits Favorable Efficacy in NSCLC
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...
The American Journal of Managed Care8 小时
Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH
An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical ...
The Pharma Letter14 小时
FDA panel votes against broader use of checkpoint blockers
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a ...
Medpage Today on MSN21 小时
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable ...